CGT
BMRN icon

Capital Guardian Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capital Guardian Trust’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-54
Closed -$5K – 238
2019
Q1 		$5K Sell
54
-27
-33% -$2.5K ﹤0.01% 292
2018
Q4 		$7K Hold
81
– – ﹤0.01% 252
2018
Q3 		$8K Buy
+81
New +$8.09K ﹤0.01% 476

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capital Guardian Trust's BMRN Position: Q2 2019 in Review

Capital Guardian Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2019, closing a stake of 54 shares — an estimated $5K sold.

Capital Guardian Trust first reported a position in BMRN in Q3 2018 and held it in 3 quarters. The position peaked at $8K in Q3 2018. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

  • Capital Guardian Trust reported no remaining BioMarin Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Capital Guardian Trust sold 54 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $5K.
  • Capital Guardian Trust first reported a position in BioMarin Pharmaceuticals in Q3 2018 and held it in 3 quarters.
  • Capital Guardian Trust's BioMarin Pharmaceuticals position peaked at $8K in Q3 2018.
  • 482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on Capital Guardian Trust's 13F filing for Q2 2019, filed 14 Aug 2019.